WHO approves Bavarian Nordic's mpox vaccine for adolescents | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
June 12, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JUNE 12, 2025
WHO approves Bavarian Nordic's mpox vaccine for adolescents

Health

Reuters
15 October, 2024, 11:40 am
Last modified: 15 October, 2024, 11:45 am

Related News

  • Argentina ratifies WHO withdrawal during US health chief's visit
  • Gaza health system at breaking point as Israeli hostilities intensify, WHO says
  • WHO members adopt global pandemic accord but US absence casts doubts
  • WHO chief says 2 million 'starving' in Gaza
  • World Health Organization looks ahead to life without the US

WHO approves Bavarian Nordic's mpox vaccine for adolescents

The WHO said in a statement that it gave the Jynneos vaccine prequalification for adolescents on Oct. 8

Reuters
15 October, 2024, 11:40 am
Last modified: 15 October, 2024, 11:45 am
The hands of a patient with skin rashes caused by the mpox virus are pictured at the treatment center of Vijana Hospital in Kinshasa, Democratic Republic of Congo August 30, 2024. Photo: REUTERS/Justin Makangara/File Photo
The hands of a patient with skin rashes caused by the mpox virus are pictured at the treatment center of Vijana Hospital in Kinshasa, Democratic Republic of Congo August 30, 2024. Photo: REUTERS/Justin Makangara/File Photo

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disease that has triggered global concern.

The WHO said in a statement that it gave the Jynneos vaccine prequalification for adolescents on Oct. 8.

The WHO declared mpox a global public health emergency for the second time in two years in August after a new type of the virus spread from the Democratic Republic of Congo to its neighbours.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The United Nations agency approved the use of the vaccine in September as the first shot against mpox in adults, making it easier for badly hit African countries to access the vaccine.

Children, adolescents and those with weakened immune systems have been particularly vulnerable to mpox, a viral infection that typically causes flu-like symptoms and skin lesions filled with pus.

WHO's latest decision comes after the EU approved the drug for the vaccine for adolescents in September.

The Danish biotech firm is also preparing to conduct a clinical trial to assess the vaccine's safety in children aged two to 12, potentially extending its use.

The trial, partially funded by the Coalition for Epidemic Preparedness Innovations, is expected to start in October.

The US Food and Drug Administration has also approved Bavarian's shot, but only for use in adults 18 years and older, although it granted Emergency Use Authorization for its use in adolescents during the mpox outbreak of 2022.

Another mpox vaccine, LC16, made by Japan's KM Biologics, can already be given to children, according to the Japanese regulator, although it requires a special kind of needle.

Bavarian Nordic did not immediately respond to a request for comment on the prequalification.

 

Africa

World Health Organisation (WHO) / Mpox Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Govt to set up Debt Office as loan burden to hit Tk29 lakh cr by FY28
    Govt to set up Debt Office as loan burden to hit Tk29 lakh cr by FY28
  • UK Secretary of State for Business and Trade and President of the Board of Trade Jonathan Reynolds meets Chief Adviser Muhammad Yunus on 11 June 2025. Photo: UNB
    UK reaffirms support for Bangladesh's initiatives to recover siphoned off money
  • File Photo of Chief Adviser Muhammad Yunus: UNB
    Prof Yunus to receive Harmony Award from King Charles today

MOST VIEWED

  • File photo of ex-prime minister Sheikh Hasina and her son Sajeeb Wazed Joy. Photo: Collected
    Joy spends Eid with Hasina in India: Indian media
  • Infofgraphics: TBS
    DGHS issues 11-point directive to prevent spread of Covid-19 in Bangladesh
  • Saifuzzaman Chowdhury. Photo: Collected
    UK crime agency now freezes assets of ex-land minister Saifuzzaman: AJ
  • File photo of BNP Standing Committee Member Amir Khasru Mahmud Chowdhury. Photo: Collected
    Khasru flies to London ahead of Yunus-Tarique meeting
  • Chief Adviser Muhammad Yunus speaks at the Chatham House in London on 11 June 2025. Photo: CA Press Wing
    No desire to be part of next elected govt: CA Yunus
  • Illustration: Khandaker Abidur Rahman/TBS
    Three hospitals ‘held hostage’ as discharged July uprising injured keep occupying beds

Related News

  • Argentina ratifies WHO withdrawal during US health chief's visit
  • Gaza health system at breaking point as Israeli hostilities intensify, WHO says
  • WHO members adopt global pandemic accord but US absence casts doubts
  • WHO chief says 2 million 'starving' in Gaza
  • World Health Organization looks ahead to life without the US

Features

Among pet birds in the country, lovebirds are the most common, and they are also the most numerous in the haat. Photo: Junayet Rashel

Where feathers meet fortune: How a small pigeon stall became Dhaka’s premiere bird market

17h | Panorama
Illustration: Duniya Jahan/ TBS

Forget Katy Perry, here’s Bangladesh’s Ruthba Yasmin shooting for the moon

1d | Features
File photo of Eid holidaymakers returning to the capital from their country homes/Rajib Dhar

Dhaka: The city we never want to return to, but always do

3d | Features
Photo collage shows political posters in Bagerhat. Photos: Jannatul Naym Pieal

From Sheikh Dynasty to sibling rivalry: Bagerhat signals a turning tide in local politics

4d | Bangladesh

More Videos from TBS

What did the Chief Advisor do on the second day of his UK visit?

What did the Chief Advisor do on the second day of his UK visit?

8m | TBS Stories
Why is Omicron XBB more contagious?

Why is Omicron XBB more contagious?

13h | TBS Stories
What did Dr. Yunus say at the Chatham House Dialogue in London?

What did Dr. Yunus say at the Chatham House Dialogue in London?

14h | TBS Today
News of The Day, 11 JUNE 2025

News of The Day, 11 JUNE 2025

15h | TBS News of the day
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net